anticonvulsant/seizures

FIELD OF THE INVENTION This invention relates to a group of novel compositions containing diphenylhydantoin and/or dextromethorphan or another compound that binds to the same sites in the brain as dextromethorphan, with substantially the same or higher affinity. Another aspect of this invention

FIELD OF THE INVENTION The present invention relates to compounds useful in treating pathological conditions, such as convulsions and spasticity, without producing undesirable excessive sedation or muscle weakness in animal subjects, including humans. More particularly, the invention relates to the

FIELD OF THE INVENTION The present invention relates to a method of treating convulsions, including convulsive tremors and convulsive seizures, and, in particular, epilepsy, with organic copper compounds. BACKGROUND OF THE INVENTION Copper is a normal component of the human brain, which contains

FIELD OF THE INVENTION The present invention relates to a method of treating convulsions, including convulsive tremors and convulsive seizures, and, in particular, epilepsy, with organic copper compounds. BACKGROUND OF THE INVENTION Copper is a normal component of the human brain, which contains

FIELD OF THE INVENTION The present invention relates to a method of convulsions, including convulsive tremors and convulsive seizures, and, in particular, epilepsy, with organic copper compounds. BACKGROUND OF THE INVENTION Copper is a normal component of the human brain, which contains about 370 mg

FIELD OF THE INVENTION The present invention relates to a method of treating convulsions, including convulsive tremors and convulsive seizures, and, in particular, epilepsy, with organic copper compounds. BACKGROUND OF THE INVENTION Copper is a normal component of the human brain, which contains

BACKGROUND OF THE INVENTION The present invention relates to a agents useful as excitatory amino acid antagonists. The quinoline and kynurenin derivatives of the present invention have affinity for the glycine binding site of the NMDA receptor. Compounds of the present invention should be usable for

BACKGROUND OF THE INVENTION The present invention relates to certain novel imidazo[4,5-b]pyridines useful as anxiolytic and anticonvulsant agents, by virtue of their ability to bind to the benzodiazepine receptors and inhibit electrically or chemically induced seizures. The preparation of fused

INTRODUCTION This invention relates the use of certain N-(2-amino-cycloaliphatic)benzamide compounds as Central Nervous System (CNS) antiseizure, e.g., anti-convulsant, drugs in valuable warm-blooded animals, including humans. BACKGROUND OF THE INVENTION Szmuszkovicz U.S. Pat. No. 4,098,904

FIELD OF THE INVENTION The present invention relates to compositions and methods for treating or preventing convulsions or seizures. BACKGROUND OF THE INVENTION Tofisopam is 1-(3,4-dimethoxy-phenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiaze- pine, which can be represented by the

FIELD OF THE INVENTION The present invention relates to compositions and methods for treating or preventing convulsions or seizures. BACKGROUND OF THE INVENTION Tofisopam is 1-(3,4-dimethoxy-phenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazep ine, which can be represented by the formula:

CROSS-REFERENCE TO RELATED APPLICATIONS This application is filed under the provisions of 35 U.S.C. .sctn.371 and claims the priority of International Patent Application No. PCT/ES2009/070201 filed on 3 Jun. 2009 entitled "Use of Statins as Anticonvulsants, Antiepileptics and Neuroprotectors" in the

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to new anticonvulsants drugs and pharmaceutical compositions containing the anticonvulsants drugs and methods of treating with the drugs. 2. Description of Related Art GABA is an inhibitory neurotransmitter which

FIELD OF THE INVENTION This invention pertains to a group of compounds which exhibit surprising anticonvulsant and neuroprotective properties, and methods for their use in controlling seizures or convulsions. The compounds are 1-phenylalkanecarboxylic acid derivatives. The invention is also directed

More specifically this invention relates to compounds of the formula ##STR1## and the tautomers thereof, wherein R.sub.1 is hydrogen of C.sub.1-4 lower alkyl, R.sub.2 is C.sub.1-4 lower alkyl, R is halogeno or trifluoromethyl, and n is zero, 1 or 2. For R, preferably halogeno represents chloro or